First-Line Axi-Cel Appears Effective in High-Risk Large B-Cell Lymphoma
At a median follow-up of 15.9 months, the median duration of response was not reached.
CAR-T Therapy
Smartphone App Helps Guide Use of CAR T-Cell, BiTE Therapy
The “myTcell” app is expected to be released in the United States in 2022.
Anakinra Can Prevent Severe CRS, ICANS After CAR T-Cell Therapy
There was 1 case of grade 3 CRS and 1 case of grade 4 CRS.
Brexu-Cel Deemed Safe, Effective for Mantle Cell Lymphoma in Real-World Study
Outcomes were similar to those seen in the ZUMA-2 trial.
Hospitalization, ED Visits Highest in First Month After CAR T-Cell Infusion
Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.
Rates of ICANS, Steroid Use Higher With Axicabtagene Ciloleucel Than With Tisagenlecleucel
Axicabtagene ciloleucel was associated with higher rates of grade 3-5 ICANS and corticosteroid use.
Study Reveals ‘Best Biomarker to Date’ for Predicting Relapse After CAR T-Cell Therapy
Minimal residual disease in the bone marrow, detected via next-generation sequencing, was “highly predictive” of relapse after treatment with tisagenlecleucel.
Poor Prognosis Seen for Patients With B-Cell Acute Lymphoblastic Leukemia Progression After CAR-T Therapy
Researchers sought to determine whether patients with B-ALL who progress after CAR-T therapy would have a poor prognosis.
CHIP May Affect Some Outcomes in Patients Receiving CAR T-Cell Therapy
CHIP was associated with higher rates of complete response and cytokine release syndrome.
Plasma Biomarkers May Help Target CAR-T Therapy for Multiple Myeloma
Researchers sought to determine whether plasma biomarkers may help enhance CAR-T therapy for patients with multiple myeloma.
- Loading...
Loading...
Next post in Multiple Myeloma
Loading... 
Loading...